United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price target boosted by equities researchers at HC Wainwright from $600.00 to $660.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 15.73% from the company’s previous close.

UTHR has been the topic of several other research reports. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company increased their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday. TD Cowen raised their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Price Performance

UTHR stock opened at $570.27 on Tuesday. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $607.89. The firm has a market cap of $24.99 billion, a PE ratio of 20.44, a P/E/G ratio of 1.72 and a beta of 0.75. The firm has a 50 day simple moving average of $502.93 and a 200 day simple moving average of $476.94.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 333,820 shares of company stock valued at $165,495,478 over the last three months. 10.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Clearstead Advisors LLC grew its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares during the last quarter. Independent Advisor Alliance lifted its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after buying an additional 28 shares during the period. Florida Financial Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after buying an additional 28 shares during the period. Finally, NDVR Inc. grew its stake in United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1 results: Tyvaso met the trial’s key endpoint in idiopathic pulmonary fibrosis (IPF), driving a sharp runup in the stock because success expands Tyvaso’s addressable market beyond pulmonary arterial hypertension. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Company press release and institutional coverage reinforced the data readout, giving investors more confidence in a potential FDA filing and commercial upside for Tyvaso in IPF. United Therapeutics reports positive results for lung drug
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (Bank of America, Wells Fargo, HC Wainwright, others) followed the TETON‑1 readout, amplifying buying pressure and pre‑market gaps. Higher targets highlight expected revenue expansion if IPF approval/commercialization succeeds. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Positive Sentiment: Sell‑side momentum: some firms (e.g., HC Wainwright) moved to Buy and raised targets materially, which supports further upside if clinical and regulatory paths stay on track. HC Wainwright raises UTHR price target to $660
• Neutral Sentiment: Valuation check: analysts and market write‑ups are reassessing UTHR’s valuation after the IPF data — positive clinical news boosts forward revenue expectations but raises near‑term valuation scrutiny. Investors should weigh upside against higher multiples. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Neutral Sentiment: Options flow and momentum trading: unusually high options activity and gap‑up headlines indicate speculative positioning that can amplify moves and volatility around catalysts (e.g., filings, guidance). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Sell‑side balance: some firms raised targets but left neutral/equal‑weight ratings, reflecting disagreement on upside vs. execution risk; that keeps upside concentrated in execution and regulatory milestones. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Near‑term caution: some commentary flags valuation and execution risk plus mixed earnings‑estimate revision trends — these could limit further near‑term gains unless management provides clear regulatory/launch guidance. United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.